)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Barinthus Biotherapeutics
Barinthus Biotherapeutics (BRNS) investor relations material
Barinthus Biotherapeutics Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary13 Mar, 2026
Strategic direction and mission
Focused on advancing next-generation immunotherapies for autoimmunity and inflammatory diseases using proprietary SNAP-TI technology.
Aims to restore immune tolerance and reduce inflammation by targeting the underlying causes of immune imbalance.
Lead candidate VTP-1000 targets celiac disease, with a broader pipeline addressing Type 1 and Type 2 diabetes.
Technology and platform
SNAP-TI platform enables co-delivery of multiple disease-associated antigens and an immunomodulator via nanoparticles.
Designed for broad antigen coverage, patient-friendly administration (IM/SC), and improved tolerability.
Preclinical data show increased Treg/Teff ratio, restoring immune homeostasis and providing antigen-specific immune tolerance.
Clinical development and pipeline
VTP-1000 is in Phase 1 trials for celiac disease; SAD portion completed with good tolerability and targeted immune response.
Preclinical and early clinical data indicate VTP-1000 reduces inflammatory cytokines and induces immune tolerance to gluten.
Pipeline includes CLY-101 (menin inhibitor for T1D/T2D) and CLY-201 (TYK2 inhibitor for T1D), both in early clinical stages.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Barinthus Biotherapeutics
- Merger with Clywedog to form a focused autoimmune/metabolic firm, cash runway through 2027.BRNS
Q4 202513 Mar 2026 - Lead celiac candidate in phase I, strong cash runway, and viral assets open for partnership.BRNSQ2 Virtual Investor Summit Event3 Feb 2026
- Promising HBV and celiac programs advance, with key data and strong financials supporting growth.BRNSGuggenheim Securities Healthcare Innovation Conference15 Jan 2026
- Board recommends all proposals at 2025 AGM, including director re-elections and compensation policy.BRNSProxy Filing2 Dec 2025
- Key votes include director re-elections, auditor appointments, and executive pay approval.BRNSProxy Filing2 Dec 2025
- Merger with Clywedog, $14.6M Q3 loss, $4.7M impairment, cash runway into 2027.BRNSQ3 20257 Nov 2025
- Q3 2024 saw $15M revenue, reduced net loss, and cash runway into Q2 2026.BRNSQ3 202415 Oct 2025
- Q2 2025 net loss rose to $21.1M as pipeline shifted to I&I and cash runway extends into 2027.BRNSQ2 20257 Aug 2025
- Antigen-specific immunotherapies advance with strong clinical progress and robust financials.BRNSCorporate Presentation7 Jul 2025
Next Barinthus Biotherapeutics earnings date
Q1 20267 May, 2026
Barinthus Biotherapeutics
Next Barinthus Biotherapeutics earnings date
Q1 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage